Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
about
Immunomodulation on the ocular surface: a reviewNovel formulations for antimicrobial peptidesEmerging treatment options for meibomian gland dysfunction.Recent patents on ophthalmic nanoformulations and therapeutic implicationsAn evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eyeA pilot study: the efficacy of virgin coconut oil as ocular rewetting agent on rabbit eyes.Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit modelComparison of the Anti-Inflammatory Effects of Artificial Tears in a Rat Model of Corneal Scraping.Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions.Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Nanocarriers for DNA Vaccines: Co-Delivery of TLR-9 and NLR-2 Ligands Leads to Synergistic Enhancement of Proinflammatory Cytokine Release.Emerging drugs for the treatment of dry eye disease.Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery.Topical delivery of ocular therapeutics: carrier systems and physical methods.An update on dry eye disease molecular treatment: advances in drug pipelines.Ophthalmic applications of lipid-based drug nanocarriers: an update of research and patenting activity.Surface Chemistry Interactions of Cationorm with Films by Human Meibum and Tear Film Compounds.Nanoemulsions: formation, properties and applications.Safety and toxicity of nanomaterials for ocular drug delivery applications.Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy.Therapeutic approaches for the delivery of TNF-α siRNA.Approaches in topical ocular drug delivery and developments in the use of contact lenses as drug-delivery devices.A novel eye drop of alpha tocopherol to prevent ocular oxidant damage: improve the stability and ocular efficacy.Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl.Preparation and optimisation of anionic liposomes for delivery of small peptides and cDNA to human corneal epithelial cells.A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatmentRelevance of Lipid-Based Products in the Management of Dry Eye Disease.Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review.Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program.Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.Design, Synthesis, and Antibacterial Activity of a Multivalent Polycationic Calix[4]arene-NO Photodonor Conjugate.Cubic liquid crystalline nanoparticles: optimization and evaluation for ocular delivery of tropicamide.Keratitis in Dry Eye Disease and Topical Ciclosporin A.Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation.
P2860
Q26740643-2D0E0C18-03DF-4C4A-8976-F5F606511907Q26991771-49D29316-11F6-4908-91A1-6ADFB4196521Q34371781-8FF7E7F8-8E18-4107-8687-54B7247832A9Q35043004-722693E9-E6C5-4B47-AD25-E73B453F9F74Q35094304-FDD5ED17-1428-4ABB-8CCE-98616724EFBEQ35157303-0DC7CDAE-E2F7-4DE4-A599-0FEB18F0EDEFQ36182937-08F0EC00-3428-4368-8EB6-1C415EB7B3E6Q36656777-EF221FB3-35B1-401D-A5D9-69C82418074AQ36981187-F2FECD04-4C0C-436C-945E-740349A154CEQ37602017-3671C9D6-9552-4D33-BD5F-BED886AA27A7Q37627442-CD6297A5-8DEA-4CE8-9D3C-F7EA409C458AQ37638619-00840D25-CD65-40E0-A7F4-5B8FB52C3536Q38102006-8A11BD99-106D-4880-AA32-3AC960C01D4BQ38133883-B9842C37-C6C3-4CE7-B037-00AB1F5F266BQ38196446-2C83435B-78EB-422E-8836-4701A7F5366EQ38207723-648D636D-657C-40F9-8745-831D9113B094Q38648168-04518037-7846-4E59-BDC2-C8FACC8E2FECQ38674125-2966A937-6679-4B92-864F-0232D763AA37Q38754120-0463BB3B-C583-47EC-9257-04BC0D71380BQ38793489-6E6DCB69-54FF-4228-9660-8C0AE3B5136DQ39103248-00C5A69B-4C03-42A6-B26A-2E6E1335EDEEQ39210558-DE57F349-8963-446B-B43E-D989985ECADCQ39386513-73ACB175-8DAB-439C-BAF0-9E4410C9A81FQ40573088-48066374-0744-43E2-A184-6B8C0E1AE1BFQ40713954-CD400D20-1449-4A66-878A-A7002D9D51D9Q41154638-53EC1993-2612-40A6-89AB-006C458795DEQ41442733-0EC77F7F-3F41-41C4-B5AB-A11D12029E7BQ43119649-0AA44702-93DB-41EB-93E2-E9AB4E969DDBQ47100458-B78FA7BB-E246-4607-B84A-6434862EAA39Q49996892-0E71B289-3322-473E-8990-092BCA4A9E6AQ50025206-EF0D6DFD-1308-4735-9FD2-A4D89DE51CBAQ51787921-81E42428-9D8C-4341-9FA7-B849779D6354Q51823285-CCE1CCE5-80F0-449B-87B2-7B97CA33893EQ53174701-D2CBED61-704C-41A1-B3C5-AE49308E358CQ53534950-97B8DE35-7810-4E20-898F-5A714306B566Q54839313-CA3F899C-1D6E-4095-B69E-B16E97BB078A
P2860
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
@ast
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
@en
type
label
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
@ast
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
@en
prefLabel
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
@ast
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
@en
P2093
P2860
P356
P1476
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.
@en
P2093
Frederic Lallemand
Jean-Sebastien Garrigue
Philippe Daull
Ronald Buggage
Simon Benita
P2860
P304
P356
10.1155/2012/604204
P577
2012-02-27T00:00:00Z